الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 113 |  |  |
| | | from | 113 | | |
Abstract
Summary
Retinal vein occlusion is the second most common retinal vascular disease after diabetic retinopathy. Branch retinal venous occlusion (BRVO) occurs the occlusion of one of the branches of the retinal vein. The occlusion occurs mostly at arteriovenous crossing and more frequent in upper temporal retinal veins.
In the current study, randomized control study was conducted on 2 groups divided into 27 eyes (Ranibizumab alone), 27 eyes (Ranibizumab and Targeted retinal laser).
The including criteria were patients that have risk factors for BRVO as chronic hyper tension, hyper cholesterolemia, hyper lipidemia, smoking, history of cardio vascular diseases, and history of glaucoma.
The excluding criteria were pregnant, have un controlled hyper tension or diabetes, have macular ischemia, had sensitivity to sodium fluorescein, or is received prior scatter laser photocoagulation, or have any other additional ocular diseases that can irreversibly compromise the visual acuity of the study eye are excluded from the study.
The BRVO is investigated by FFA and OCT-Macula and macular edema is measured by OCT-Macula. And the current result shows highly statistically significant improvement in visual acuity and reducing macular edema (decrease foveal thickness)with P value <0.001 in Ranibizumab alone compared with Ranibizumab and retinal laser.